Form 4: Cumberland Pharmaceuticals CFO John Hamm Reports Share Withholding for Tax Obligations
SEC Form 4 Filing
John Hamm, CFO of Cumberland Pharmaceuticals, reports the withholding of shares to cover tax obligations related to vesting shares.
Summary
- On March 16, 2025, John Hamm, the VP and CFO of Cumberland Pharmaceuticals, reported a transaction involving common stock.
- 5,930 shares were withheld by the company to cover tax withholding obligations for the vesting of shares at a price of $5.46.
- Following the transaction, Hamm directly owns 20,073 shares of common stock.
- Hamm also acquired 2,750 options (right to buy) at $5.17 on March 17, 2025, exercisable from March 17, 2029, to March 17, 2035.
- Following the transaction, Hamm directly owns 15,250 options.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's securities.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the withholding of shares for tax purposes, which is a normal part of equity compensation.
Key Dates
| Date | Description |
|---|---|
| 03/16/2025 | Date of transaction involving common stock where shares were withheld for tax obligations. |
| 03/17/2025 | Date of acquisition of options (right to buy). |
| 03/17/2029 | Date options become exercisable. |
| 03/17/2035 | Expiration date of options. |
| 03/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.